1naresh
Array
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
1nareshArray
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
Table 1: Demographic, clinical, and neuroimaging features in patients with PSP-P, PSP-RS, PD, and healthy controls
PSP-P (n = 9) PSP-RS (n = 21) PD (n = 20) HC (n = 30) Age (mean) (yr) 70.1 ± 4.8 71.9 ± 5.9 66.2 ± 3.0 67.2 ± 7.2 Sex, % male 100% 57% 50% 47% Disease duration (mean) (yr) 6.3 ± 3.7 3.1 ± 1.4 7.5 ± 3.7 – MMSE (mean) 22.1 ± 3.6 19.0 ± 5.4 23.2 ± 3.3 – UPDRS-III (mean) 22.8 ± 17.7 39.3 ± 7.7 27.1 ± 9.1 – HY (mean) 2.9 ± 0.7 3.4 ± 0.8 2.2 ± 0.5 – SCP right Volume (No. of voxels) (mean) 5652 ± 1172 5282 ± 753 6907 ± 1306 6569 ± 944 FA (mean) 0.44 ± 0.05 0.40 ± 0.05 0.48 ± 0.04 0.45 ± 0.02 MD (×10−3 mm2/s) (mean) 0.873 ± 0.06 0.949 ± 0.170 0.851 ± 0.089 0.833 ± 0.031 SCP left Volume (No. of voxels) (mean) 5315 ± 1121 4812 ± 701 6369 ± 1205 5961 ± 894 FA (mean) 0.44 ± 0.04 0.39 ± 0.05 0.47 ± 0.04 0.45 ± 0.02 MD (×10−3 mm2/s (mean) 0.895 ± 0.061 0.974 ± 0.074 0.874 ± 0.066 0.857 ± 0.023
Note:—HC indicates healthy controls; MMSE, Mini-Mental State Examination; UPDRS-III, Unified Parkinson's Disease Rating Scale–Motor Examination; HY, Hohen and Yahr score.